REGENXBIO (NASDAQ: RGNX) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
This is a summary of current ratings and recommmendations for REGENXBIO and Five Prime Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Five Prime Therapeutics||0||0||6||0||3.00|
REGENXBIO presently has a consensus target price of $43.17, suggesting a potential upside of 46.58%. Five Prime Therapeutics has a consensus target price of $67.75, suggesting a potential upside of 186.59%. Given Five Prime Therapeutics’ higher probable upside, analysts plainly believe Five Prime Therapeutics is more favorable than REGENXBIO.
Institutional & Insider Ownership
68.7% of REGENXBIO shares are owned by institutional investors. Comparatively, 83.8% of Five Prime Therapeutics shares are owned by institutional investors. 17.0% of REGENXBIO shares are owned by company insiders. Comparatively, 6.5% of Five Prime Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares REGENXBIO and Five Prime Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Five Prime Therapeutics||-408.42%||-41.57%||-35.39%|
Valuation & Earnings
This table compares REGENXBIO and Five Prime Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|REGENXBIO||$4.59 million||199.86||-$62.96 million||($2.71)||-10.87|
|Five Prime Therapeutics||$30.69 million||22.28||-$65.69 million||($5.06)||-4.67|
REGENXBIO has higher earnings, but lower revenue than Five Prime Therapeutics. REGENXBIO is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.
REGENXBIO Company Profile
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
Receive News & Ratings for REGENXBIO Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for REGENXBIO Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.
Sumber berita :